Articles tagged with Pancreatic Cancer
A new study found that Ga-68 FAPI PET imaging can effectively detect and stage pancreatic cancer, outperforming existing methods. The imaging modality also showed potential for future targeted radiopharmaceutical therapies.
A drug screening system modeling cancers with lab-grown tissues called organoids helped uncover a promising target for future pancreatic cancer treatments. Researchers identified an existing heart drug, perhexiline maleate, that powerfully suppresses the growth of pancreatic tumor organoids.
A novel inhibitor drug, KRB-456, has been discovered to target the KRAS G12D mutation in pancreatic cancer patient-derived tumors. The study demonstrates that KRB-456 significantly inhibits tumor growth in mice, offering a promising therapeutic option for KRAS-driven cancers.
Researchers at Salk Institute discovered how anti-cancer drugs can prevent fibroblast activation, a protective barrier around pancreatic tumors. The therapy reduces tumor growth and slows disease progression in mice and human patients, offering a promising treatment for pancreatic cancer.
A recent study from Drexel University's College of Nursing and Health Professions aimed to understand the challenges and supports affecting individuals with GI cancer and their caregivers when it comes to maintaining a healthy diet and avoiding malnutrition. The research highlighted the importance of creating dietary interventions that...
Researchers found that secreted frizzled-related protein 2 (SFRP2) is abundantly expressed in pancreatic cancer, with higher levels linked to poorer outcomes. Blocking SFRP2 may affect tumor growth, angiogenesis, and the immune system, making it a potential therapeutic target.
Researchers confirm that pancreatic cancer triggers a response in the immune system, but T cells struggle to infiltrate tumors. This finding could guide future treatment development for pancreatic ductal adenocarcinoma (PDAC), a deadly form of pancreatic cancer.
Researchers developed a new radiation therapy approach combining a sensitizing drug with stereotactic body radiation therapy, resulting in higher progression-free survival and overall response rates. The treatment reduced toxicity while increasing its effectiveness in treating locally advanced pancreatic cancer.
Researchers have made a breakthrough in understanding the genetic changes that occur during tumor migration, and discovered a drug that can obstruct this process. A new clinical trial at the University of Rochester's Wilmot Cancer Institute will test the effectiveness of the experimental drug NP137.
A long-term study published in Environmental Epidemiology shows a slightly increased incidence of cancer, particularly colon, pancreas, and stomach cancer in men, as well as lymphoma in women. The researchers used new calculation methods to analyze radiation doses from Chernobyl fallout.
Scientists at Nagoya University have discovered a reliable cancer marker, stromal cell-derived factor 4 (SDF-4), that detects gastric cancer with high accuracy. The protein is found in high levels even in patients with stage I gastric cancer, suggesting its potential for early detection.
A new model reveals how a single pool of stem and progenitor cells in the pancreas can give rise to multiple types of pancreatic cancer. The study suggests that understanding the cell from which a cancer arises can help researchers develop therapies tailored to an individual's disease.
Men who are overweight or obese at age 18 have a higher risk of developing 17 different cancers later in life. Higher BMI is also associated with an increased risk of mortality after cancer diagnosis for certain types of cancer.
Researchers at Mainz University Medical Center aim to improve patients' quality of life by applying smart data technology to physical activity. The DECIDE project aims to provide individualized control of patients' daily physical activity, while the RELEVIUM project focuses on alleviating pain and weight loss in pancreatic cancer patie...
Researchers at University of British Columbia find a direct link between high insulin levels and pancreatic cancer, highlighting the importance of keeping insulin levels within a healthy range. The study suggests that excessive insulin overstimulates pancreatic acinar cells, leading to inflammation and precancerous cell development.
The partnership aims to reduce disparities in cancer research and drug development through collaborations, resources, and training programs. Key projects will focus on breast and pancreatic cancers, particularly luminal B breast cancers disproportionately affecting women of African descent.
A new AI-based tool estimates patient-specific cancer survival rates using machine learning, offering personalized prognosis for patients with breast, thyroid, and pancreatic cancers. The Cancer Survival Calculator differs from existing estimators by incorporating multiple factors beyond disease stage.
Researchers found amoeboid cells in pancreatic cancer produce CD73, which drives spread and weakens immune system. Blocking CD73 reduced cancer spread to liver and decreased immune cell support.
Researchers at Osaka University have developed a novel radioactive antibody that can diagnose and treat a deadly type of pancreatic cancer. The antibody targets glypican-1, a protein highly expressed in PDAC tumors, allowing for early detection and treatment with improved survival rates.
A University of Massachusetts Amherst team demonstrates a protein antigen from a childhood vaccine can be delivered into malignant tumor cells to refocus the immune system against cancer. The bacteria-based intracellular delivering system shows promise in treating pancreatic, liver, and metastatic breast tumors.
Researchers at Sanford Burnham Prebys have developed a new approach to treat pancreatic cancer by feeding tumors a copycat of the important nutrient glutamine. This method significantly slowed pancreatic tumor growth and prevented the spread of tumors in early clinical trials.
The study developed a highly accurate AI model for fully automated cancer detection, including small and difficult-to-detect tumors. The model could detect visually imperceptible cancer from normal-appearing pancreases substantially early before clinical diagnosis, with a median of 438 days.
Researchers have discovered a new mechanism for starving pancreatic cancer cells, potentially leading to improved treatment outcomes. A combination of treatments involving the drug DRP-104, which blocks glutamine metabolism, and trametinib, an existing ERK signaling pathway blocker, showed promising results in mouse models.
Armida Labs, a UCR-founded pharmaceutical company, has received a $400,000 NIH Small Business Innovation Research grant to develop its breakthrough pancreatic cancer therapy Targefrin. The grant will enable the company to gather industry-standard data for human clinical trials.
A Rice University-led team of researchers has been awarded $45 million to develop a new sense-and-respond implant technology that could improve immunotherapy outcomes for patients with difficult-to-treat cancers. The technology, called THOR, aims to provide real-time data from the tumor environment to guide more effective therapies.
Scientists have identified a DNA methylation pattern that can accurately diagnose pancreatic cancer, distinguishing it from chronic pancreatitis. The marker, which involves six specific methylation positions in the PRKCB gene, has been validated on tissue and blood samples, offering hope for improved diagnosis and treatment.
Researchers developed a reliable and reproducible real-time live tissue sensitivity assay (RT-LTSA) using fresh tumor samples to predict patients' clinical response to chemotherapy. The study showed improved disease-free survival and reduced recurrence rates in patients who received RT-LTSA sensitive adjuvant regimens.
Researchers have discovered two FDA-approved and EMA-approved drugs that inhibit prmt5, a protein linked to promoting tumor growth in several cancers. These repurposed drugs show promise in reducing cancer cell proliferation and tumor growth.
Preclinical data shows GP-2250's antineoplastic activity in pancreatic tumor cell lines, reducing ATP levels and inhibiting NF-kB. The compound targets aerobic glycolysis, a hallmark of cancer metabolism, providing a potential treatment for various cancers.
Salk researchers have identified a new set of molecules that fuel the growth of tumors in pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer. The study found that activating a super-enhancer leads to an increase in protein production, enabling rapid cell growth.
Researchers at MD Anderson successfully reduced inpatient opioid use by 50% and median prescription volumes to zero after pancreatic cancer surgery. This approach achieved effective pain control for patients without increasing the risk of opioid dependence.
A novel liquid biopsy technology developed by UCSC Assistant Professor Daniel Kim's lab leverages RNA 'dark matter' to enhance cancer diagnosis. The test detects both protein-coding and repetitive noncoding RNAs in the blood, showing improved sensitivity for early-stage cancer detection.
A new Australian drug, PXS-5505, has shown promise in treating aggressive pancreatic cancer by targeting fibrotic tissue within tumours. The drug combination therapy significantly reduced fibrosis and improved chemotherapy effectiveness, increasing survival time by over 35%.
Benzodiazepine lorazepam is associated with shorter progression-free survival in pancreatic cancer patients. In contrast, alprazolam use was linked to a longer progression-free survival. Lorazepam may activate GPR68, boosting IL-6 expression and promoting tumor growth in the pancreatic microenvironment.
Patients with cancer who live in rural Pennsylvania counties are more likely to receive complex surgeries at high-volume hospitals due to their perceived better outcomes. However, for less complex surgeries, rural patients are less likely to opt for high-volume hospitals despite potential benefits from centralization.
Researchers at Sylvester Comprehensive Cancer Center will investigate signaling mechanisms between myeloid-derived suppressor cells and pro-inflammatory cancer-associated fibroblasts in pancreatic cancer. The goal is to develop a nanoengineered immunotherapy that selectively disrupts these interactions to target treatment resistance.
A large long-term study found that good cardiorespiratory fitness in young men is associated with a significantly lower risk of developing nine specific cancers, including a 40% reduced risk of liver cancer. Higher fitness was also linked to lower risks of rectal, pancreatic, and bowel cancers.
A study published in Nature found no link between the pancreatic microbiome and the development of pancreatic cancer, contradicting earlier findings that suggested a potential method for preventing the disease. The researchers reanalyzed data from an original study and used pancreatic cancer tissue samples to confirm their results.
Researchers aim to treat pancreatic ductal adenocarcinoma by targeting amino acid transporter SLC6A14 and compensatory nutrient scavenging mechanisms autophagy and macropinocytosis. Using alpha-methyl-L-tryptophan and hydroxychlorquine, the study seeks to improve therapeutic outcomes in patients with pancreatic cancer.
Researchers discovered that high blood glucose levels make pancreatic cancer cells more sensitive to chemotherapy, which could lead to improved treatment outcomes. In a mouse model and clinical data, the study found a nearly 40% lower risk of death among patients with elevated glucose levels compared to those with normal levels.
A new combination treatment of GVAX vaccine, nivolumab, and urelemab has shown to increase the amount of cancer-killing immune cells in tumors and appear effective when given two weeks prior to surgery. The study found a median disease-free survival of 33.51 months and a median overall survival of 35.5 months.
Amplified Sciences has received a $400,000 NCI grant to develop and validate an assay testing for the detection of pancreatic cancer in patients diagnosed with pancreatic cystic lesions. The company aims to improve the accuracy of diagnoses, reducing unnecessary surgical interventions.
Researchers at Kumamoto University identified a cell surface marker, ROR1, that promotes hyperproliferation and metastasis in pancreatic cancer. High expression of ROR1 drives tumorigenicity and intratumor heterogeneity, suggesting a potential therapeutic target for pancreatic cancer therapy.
A Mayo Clinic study reveals that minimally invasive surgical procedure staging laparoscopy can identify cancer spread early and determine the stage of pancreatic cancer. The research found a higher risk of cancer spread in patients with certain factors, such as age and tumor markers.
A study found disparities in Hispanic cancer mortality rates, with higher rates for men in certain age groups and women for liver, pancreatic, and uterine cancers. The researchers highlight the need for targeted education and screening efforts to address these disparities.
Researchers at UC San Diego found a novel combination of KRAS and ERBB drug inhibitors outperformed treatments in human and mouse models of pancreatic cancer. The combination reduced drug resistance and increased survival rates.
The study, published in JAMA Oncology, found that the percentage of cancer survivors reporting functional limitations has more than doubled over the past 20 years. The adjusted prevalence of functional limitation was highest among pancreatic and lung cancer survivors, while melanoma survivors had the lowest rate.
Researchers found that only 6.8% of cancer patients underwent genetic testing within two years of diagnosis, with lower rates among Black, Hispanic, and Asian patients. The low rates are attributed to lack of integration of test results into cancer management and prevention.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
UMC Utrecht researchers are conducting two new projects to treat cancer using image-guided interventions. One project uses MRI-guided radiotherapy for locally advanced pancreatic cancer, while the other employs ultrasound techniques for head and neck cancers.
Researchers have discovered that HER3 plays a crucial role in promoting cell survival in metastatic colorectal and pancreatic cancer. The surrounding liver microenvironment activates HER3, making it an emerging therapeutic target for these types of cancer.
Researchers at Michigan Medicine have discovered a new nutrient source that pancreatic cancer cells use to grow in the absence of glucose. Uridine is found in the tumor microenvironment and its exact source remains unknown. Blocking uridine metabolism may lead to new treatment options for pancreatic cancer.
Research reveals both metabolically healthy and unhealthy obesity types linked to increased risk of various obesity-related cancers, with stronger association in metabolically unhealthy obesity. Metabolically unhealthy women face higher risks for endometrial, liver, and kidney cancers.
SpaceMarkers, a new machine learning software, can identify molecular interactions among distinct cell types in and around tumors. By analyzing spatial transcriptomics data, it reveals genes overexpressed due to cell-to-cell interactions, providing new avenues for understanding cancer progression and treatment responses.
Scientists have developed a gene-editing technique that allows them to easily engineer specific cancer-linked mutations into mouse models. This new method, based on CRISPR genome-editing technology, enables researchers to explore many unknown mutations and develop new drugs targeting those mutations.
Scientists have identified a specific gene mutation that triggers an inflammatory cascade, driving the development of treatment-resistant cancers. The study reveals a molecular circuitry by which mutations in the STK11 gene cause inflammation to spiral out of control.
A new study in mice reveals that pancreatic cancer's emergence is fueled by the expansion of cell-to-cell communication. Researchers found that plasticity and inflammation reshape cells' identities and local environments, fostering cancer growth. The study provides insights into the earliest cellular events leading to PDAC and potentia...
An AI tool has identified people at highest risk for pancreatic cancer, suggesting population screening could expedite diagnosis and improve outcomes. The model predicted disease occurrence with accuracy comparable to genetic sequencing tests, targeting those at elevated risk without relying on family history or genetic mutations.
A research tool developed at the Garvan Institute has uncovered unprecedented detail about pancreatic cancer drug response and resistance. The molecule AKT, a key driver of cancer growth and spread, is activated in distinct parts of the tumour, including areas of low oxygen supply where it forms pockets of resistance to therapy.
Researchers at the University of Colorado Cancer Center have made a breakthrough in treating pancreatic cancer by combining radiation and immunotherapy. The treatment eradicates tumors while stopping the cancer from spreading, offering new hope for patients. Clinical trials are planned to further develop this therapy.